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Fibrosis Australia, Sydney, NSW, Australia
Developments in cystic ﬁbrosis data registries are creating opportunities to compare
patient outcomes and aspects of clinical practice between treatment centres. In fact,
the ability to make such comparisons is one of the reasons for the establishment
and maintenance of national registries. The large, long established patient registry
of the United States Cystic Fibrosis Foundation has been used effectively for such
purpose (Gawande 2004, Schechter and Margolis 2005). Smaller national registries
do not have the numbers to replicate such outputs. For this reason, as well as
broader interest in sharing knowledge internationally for the beneﬁt of people
with cystic ﬁbrosis, extension to international benchmarking is of interest. Interim
arrangements for sharing a limited range of indicators have been explored between
the US and Australian registries. Informal discussions with registry managers from
other countries have revealed wider interest in pursuing an international arrangement
for benchmarking treatment centres across countries.
A proposal to extend benchmarking to an international level raises a range of
issues, including those relating to standardisation of data, risk adjustment and others
relating to governance of benchmarking arrangements. The presentation will outline
ideas for the purpose of facilitating discussion in an international cystic ﬁbrosis
forum, perhaps leading to a plan to proceed towards international benchmarking
using registry data.
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Background: Survival in cystic ﬁbrosis (CF) has increased over the past 30 years,
but there are few recent data on gender differences in mortality.
Methods: We used national mortality data obtained from the Australian Institute
of Health and Welfare to identify all individuals registered as having died from CF
between 1979 and 2005. We matched these data with information obtained from
Australian transplant centres to remove lung transplantation as a confounder for
age at death.
Results: The mean age of death increased from 12.4 years in 1979 to 26.7 years in
2005. There was a substantial fall in mortality rate in the 0−14 years age group with
a corresponding increase in mortality rate in the 15−39 years group and small rise
in mortality rate in the 40−59 years age group. Female mortality rate, particularly
in the 0−14 years age group consistently and signiﬁcantly exceeded that of males,
although the magnitude of this difference has decreased from 1997 onwards. Males
and females demonstrated two quite distinct reductions in childhood mortality; in
males there was a rapid reduction in mortality rate in the 0−14 years age group
after 1986 whereas there was a later and similar rapid reduction in mortality rate
in females aged 0−14 years age group observed from 1997 onwards.
Discussion: This is the ﬁrst comprehensive analysis of CF mortality in Australia.
Although CF survival has increased over the past 25 years, female mortality rates
continue to exceed those of males, but this gender imbalance is becoming less.
Supported by: Australian Cystic Fibrosis Research Trust.
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This study aimed to report the data of mortality (rates and causes) registered in a
cohort of patients born since 1970 in Brittany (Western France).
During the 1970–2008 period, 559 patients were born, including 250 since newborn
screening was implemented in 1989. On dec. 31st 2008, 174 deaths were recorded
(31.1%), only 10 in the screened cohort and none in the group of those born since
2000. Mean age at death was 12.9 y. [0.0−37.7]. The deaths arise more frequently
before the age of 10 y. in the 1970−79 group (40.9%) than in the 1980−89 one
(30.5%). Deaths in the teen ages are more frequent in the second group than in the
ﬁrst one (42.3% vs. 26.6%). It was not possible to spread the comparison to other
decades, because of censored observations.
Reasons of death were known for 123/174 patients (70.7%). In most cases (n = 90
70.3%) death was consecutive to respiratory failure and in 12 cases (9.8%) related
to post-transplant failure. Mean ages at deaths were respectively 15.5 y. and 21.4 y.
Haemoptysis are responsible for 3 deaths (2.4%) and cardiac disorders for 2 (1.6%).
Mean ages were 17.1 & 24.4 y. respectively. Nine deaths were recorded in early
childhood including 5 due to meconium ileus (4%). Others were unrelated to CF
(acute suffering at birth, SID, T21,. . . ). The other registered causes were accidents,
drug abuse, suicide and concern young adults (19.2 y. meanly).
Among the screened patients, 7 of the 10 deaths occurred near to birth (IM, SID)
and 3 in adolescents with respiratory symptoms.
One can note a delay of the age at death between groups. Among the screened
patients, very few deaths were registered (10/250) and most of them were not
imputable to CF. No death occurred in the earliest generations.
Supported by: Programme Hospitalier de Recherche Clinique.
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Introduction: Although survival in CF is improving, most patients still die before
their 5th decade. Despite this, few studies have focussed on end-of-life care and
the mode of death. To look at this, we audited these issues in patients who had
deceased at our large adult unit between 1997–2008.
Patients and Methods: We reviewed the case records of 60 patients, paying
attention to basic epidemiology, microbiological status, transplant referral, end of
life care, and the cause of death.
Results: Mean age at death was 28 years [range 17 to 58], 32 women (53%): 45
(76%) were infected by the Liverpool Epidemic Pseudomonas aeruginosa strain,
11 (18%) by Burkholderia cenocepacia and 4 (6%) had CF related diabetes. Eight
(13%) had liver disease, 4 with portal hypertension. Thirty two (53%) were DF508
homozygous. Twenty (34%) were referred for lung transplantation: in 5 it was
declined by patient, 5 by the transplant centre, and only 3 received a transplant.
Two other patients had liver transplantation. During the terminal phase, 4 (6%)
had renal failure and 16 (27%) liver failure. End of life care included opiate based
infusions via a syringe driver in 49 (81%). Only 10 (16%) were given BIPAP during
their last admission. Four patients preferred to die at home.
Conclusion: This review shows that, whilst progressive respiratory failure is still
the commonest cause of death in CF, an increasing number of patients are dying
from other complications of the CF condition, in particular liver disease for which
there is no effective preventative treatment. More attention needs to be paid to end
of life care issues in the adult CF population.
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66% 15% 5% 3% 1.6% 1.6% 3% 3%
